Belgium· BE-AMP-SAM460062-00
Corbilta 100 mg - 25 mg - 200 mg
A levodopa, decarboxylasehemmer und comt-hemmer product containing levodopa, registered in Belgium by Orion. The same ATC class is registered in 12 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Levodopa, decarboxylasehemmer und comt-hemmer is registered in 12 of 19 countries.
Countries holding a registration under ATC N04BA03 (levodopa, decarboxylasehemmer und comt-hemmer), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Levodopa, decarboxylasehemmer und comt-hemmer · ATC N04BA03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of levodopa, decarboxylasehemmer und comt-hemmer costs, country by country.
Normalised to the WHO defined daily dose (0.45 g), the median price runs from $1.36 in Italy to $5.49 in Switzerland — a ×4.0 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Levodopa, decarboxylasehemmer und comt-hemmer · price per daily dose (0.45 g)
USD · FX 28 Sept 2026
- CH Switzerland$5.49
- IT Italy$1.36
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Levodopa
- Manufacturer
- Orion
- Country
- Belgium (BE)
- ATC code
- N04BA03
- ATC class
- Levodopa, Decarboxylasehemmer und COMT-Hemmer
- Defined daily dose
- 0.45 g, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
1 priced- be_apb7709256
- be_apb3167525EUR 49.32
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
158 interactions on record for levodopa, decarboxylasehemmer und comt-hemmer.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Levodopa, decarboxylasehemmer und comt-hemmer · interactions on record
158 records
- 4 severe
- 122 moderate
- 14 minor
Most severe, free to view
- ProcarbazineL01XB01severe
- OzanimodL04AA38severe
- OzanimodL04AE02severe
- Methylthioninium chlorideV03AB17severe
18 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Levodopa, decarboxylasehemmer und comt-hemmer in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesInbrijaMerz Pharmaceuticals, LLC
- United KingdomInbrija 33mg inhalation powder capsules with deviceMerz Pharma UK Ltd
- CzechiaINBRIJAMerz Therapeutics GmbH, Frankfurt am Main
- FinlandDoparkinOrion Corporation Orion Pharma
- IcelandInbrijaMerz Therapeutics GmbH
- NetherlandsInbrija 33 mg inhalatiepoeder, harde capsulesMerz Therapeutics GmbH
- NorwayInbrijaMerz Therapeutics GmbH
- PolandInbrijaAcorda Therapeutics Ireland Limited
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Inbrija
- Iceland · Inbrija
- Liechtenstein · Inbrija
- Norway · Inbrija
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c5c59a1c-5c37-4266-848f-db947180b450 GET /v1/drugs/c5c59a1c-5c37-4266-848f-db947180b450?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Corbilta 100 mg - 25 mg - 200 mg",
"name_fr": "Corbilta 100 mg - 25 mg - 200 mg",
"name_nl": "Corbilta 100 mg - 25 mg - 200 mg",
"amp_code": "SAM460062-00",
"strengths": [
"100.0000",
"25.0000",
"200.0000",
"1.6000"
],
"pack_count": 6,
"substances": [
"Levodopa",
"Carbidopa",
"Entacapone",
"Glycerol",
"Sucrose",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Levodopa, Decarboxylase Inhibitor and COMT Inhibitor",
"authorisation_numbers": [
"EU/1/13/859/012",
"EU/1/13/859/014",
"EU/1/13/859/013",
"EU/1/13/859/016",
"EU/1/13/859/015",
"EU/1/13/859/017"
]
}See everything about levodopa, decarboxylasehemmer und comt-hemmer.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.